Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study
Titel:
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study
Auteur:
Ahn, Myung-Ju Han, Ji-Youn Lee, Ki Hyeong Kim, Sang-We Kim, Dong-Wan Lee, Yun-Gyoo Cho, Eun Kyung Kim, Joo-Hang Lee, Gyeong-Won Lee, Jong-Seok Min, Young Joo Kim, Jin-Soo Lee, Sung Sook Kim, Hye Ryun Hong, Min Hee Ahn, Jin Seok Sun, Jong-Mu Kim, Heung Tae Lee, Dae Ho Kim, Sohee Cho, Byoung Chul